RBC Capital Maintains Outperform Rating on Verastem, Sets $19 Target
RBC Capital maintained its Outperform rating on Verastem and a $19.00 price target. The target implies 146.4% upside from the Oct. 14 close of $7.71.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.